Exploring the Therapeutic Potential of MIR ‐140‐3p in Osteoarthritis: Targeting CILP and Ferroptosis for Novel Treatment Strategies
Cell Proliferation · 2025-11 · 58 (11)
DOI: 10.1111/cpr.70018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, online erschienen am 05.03.2025. Verfasst von Feng Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan, China. Hauptthemen laut MEDLINE: MicroRNAs, Ferroptosis, Osteoarthritis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ningxia, Ningxia Hui Autonomous Region's Key R&D Program for Foreign Scientific and Technological Cooperation Projects, Natural Science Foundation of Ningxia Province.
Abstract (Originalsprache)
Osteoarthritis (OA) is a prevalent and debilitating joint disorder that affects millions of individuals worldwide, severely impairing mobility, independence, and quality of life. Emerging evidence suggests that ferroptosis is a critical factor in OA pathogenesis. However, its precise involvement and underlying mechanisms remain poorly understood. In this study, we first identified that cartilage intermediate layer protein (CILP) mediates the regulation of ferroptosis‐related genes in OA through hdWGCNA analysis combined with single‐cell RNA sequencing. Further investigation revealed a significant upregulation of CILP protein expression in C28/I2 cells under LPS induction. Mechanistically, bioinformatics analysis identified differentially expressed miRNAs; qRT‐PCR combined with a dual‐luciferase experiment revealed that miR‐140‐3p was downregulated and directly targets CILP. Experimental data further demonstrated that miR‐140‐3p regulates ferroptosis, inflammation, and oxidative stress by targeting CILP. These findings offer valuable insights into the molecular mechanisms of the miR‐140‐3p/CILP axis in regulating ferroptosis, inflammation, and oxidative stress, thus providing a foundation for developing therapeutic strategies for OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan, China.
- General Hospital of Ningxia Medical University, Yinchuan, China.
- Western Institute of Digital-Intelligent Medicine, Chongqing, China.
- Clinical Medical College, Southwest Medical University, Luzhou, China.
- Ningxia Key Laboratory of Vascular Injury and Repair Research, Yinchuan, China.
- Department of General Surgery, Dazhou Central Hospital, Dazhou, China.
ORCID-Profile: Lexin Wang
Förderung
- Ningxia
- Ningxia Hui Autonomous Region's Key R&D Program for Foreign Scientific and Technological Cooperation Projects
- Natural Science Foundation of Ningxia Province
- Medical Research Foundation of Chongqing GeneralHospital ( Y2023YXYJMSXM04 )
Zitieren
APA
Ma, F., Wang, L., Chi, H., Li, X., Xu, Y., Chen, K., Zhou, J., Yang, R., Liu, J., Xu, K., & Yang, X. (2025). Exploring the Therapeutic Potential of MIR ‐140‐3p in Osteoarthritis: Targeting CILP and Ferroptosis for Novel Treatment Strategies. Cell Proliferation, 58(11). https://doi.org/10.1111/cpr.70018
Vancouver
Ma F, Wang L, Chi H, Li X, Xu Y, Chen K, et al. Exploring the Therapeutic Potential of MIR ‐140‐3p in Osteoarthritis: Targeting CILP and Ferroptosis for Novel Treatment Strategies. Cell Proliferation. 2025;58(11). doi:10.1111/cpr.70018
BibTeX
@article{Ma2025,
author = {Ma, Feng and Wang, Lexin and Chi, Hao and Li, Xinyi and Xu, Yaoqin and Chen, Kexin and Zhou, Jingfan and Yang, Runqin and Liu, Jie and Xu, Ke and Yang, Xiaoling},
title = {Exploring the Therapeutic Potential of MIR ‐140‐3p in Osteoarthritis: Targeting CILP and Ferroptosis for Novel Treatment Strategies},
journal = {Cell Proliferation},
year = {2025},
volume = {58},
number = {11},
doi = {10.1111/cpr.70018}
}
EUVIMED